Alkermes plc buy melinda
Start price
19.06.17
/
50%
€51.55
Target price
05.07.17
€54.12
Performance (%)
5.28%
End price
05.07.17
€54.27
Summary
This prediction ended on 05.07.17 with a price of €54.27. With a performance of 5.28%, the BUY prediction by melinda for Alkermes plc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 19.048% | 19.048% | 10.294% | 15.385% |
| iShares Core DAX® | 4,85 % | -4,42 % | 13,10 % | 46,14 % |
| iShares Nasdaq 100 | 4,00 % | -3,28 % | 31,34 % | 76,07 % |
| iShares Nikkei 225® | 4,22 % | -6,22 % | 44,47 % | 47,14 % |
| iShares S&P 500 | 3,32 % | -3,17 % | 24,36 % | 57,68 % |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
genehmigt (FDA)
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.